首页 › 弥漫性大B细胞淋巴瘤 › 马萨诸塞州 › Boston
Boston MA 弥漫性大B细胞淋巴瘤临床试验
16项针对 弥漫性大B细胞淋巴瘤的研究正在 Boston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Dana Farber Cancer Institute, Boston
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
招募中3 期
- Beth Israel Deaconess Medical Center, Boston
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
招募中2 期
- Beth Israel Deaconess Medical Center ( Site 0161), Boston
- Dana Farber Cancer Institute ( Site 0111), Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
招募中1/2 期
- Dana-Farber Cancer Institute ( Site 1013), Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
招募中2 期
- Boston Medical Center, Boston
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
招募中观察性研究
- Dana Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
招募中1 期
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
招募中1 期
- Massachusetts General Hospital, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
招募中2 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
其他城市的 弥漫性大B细胞淋巴瘤试验
- New York City, NY21 项研究
- Baldwin Park, CA19 项研究
- Chicago, IL18 项研究
- Los Angeles, CA17 项研究
- Houston, TX17 项研究
- Milwaukee, WI16 项研究
- Portland, OR15 项研究
- Philadelphia, PA15 项研究
- Nashville, TN14 项研究
- Durham, NC14 项研究
- Dallas, TX13 项研究
- Washington, DC12 项研究
Boston的其他研究
- 乳腺癌110 项研究
- 非小细胞肺癌89 项研究
- 癌症（所有类型）86 项研究
- 结直肠癌63 项研究
- 转移性癌症63 项研究
- 卵巢癌62 项研究
- 肺癌62 项研究
- 前列腺癌61 项研究
- 抑郁症51 项研究
- 子宫内膜癌50 项研究
- 急性髓系白血病45 项研究
- 胰腺癌44 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年9月29日。每项研究自行设定入选标准，由研究团队决定谁能参与。